After the death of a 14-year-old patient in a clinical trial because of Amgen's Sensipar, the Food and Drug Administration has given orders to restrict the use of Sensipar in pediatric patients' clinical studies. However, the agency has not revealed about the surety of the drug having killed the boy.
Lombard Medical Technologies had developed a device dubbed Aorfix stent. It has been revealed that the US Food and Drug Administration has given green signal to the company for the new product.
The aim of the firm is to increase its operations at its Scottish manufacturing plant. And probably, the approval means the company's first step on the way to enhancing operations.
Patients of multiple myeloma can now be a bit relieved since a new drug for the disease has received green signal from the US Food and Drug Administration.
The drug named Pomalyst has been manufactured by Celgene Corp. for patients whose condition worsened following treatment with other cancer drugs.